{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:52:31Z","timestamp":1792803151801,"version":"4.5.0"},"reference-count":133,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jchf.2025.102658","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T08:01:58Z","timestamp":1758787318000},"page":"102658","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pathophysiology and Therapeutic Needs in Nonobstructive Hypertrophic Cardiomyopathy"],"prefix":"10.1016","volume":"13","author":[{"given":"Milind Y.","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccolo","family":"Maurizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Biagini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Charron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Gonz\u00e1lez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L.","family":"van Haelst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina Hermann","family":"Haugaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Meder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Michels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Yuasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2025.102658_bib1","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.amjcard.2023.10.074","article-title":"Medical treatment strategies for hypertrophic cardiomyopathy","volume":"212s","author":"Hutt","year":"2024","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib2","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2025.102658_bib3","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1016\/j.amjcard.2017.08.048","article-title":"Interaction of adverse disease related pathways in hypertrophic cardiomyopathy","volume":"120","author":"Rowin","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib4","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","article-title":"Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction","volume":"114","author":"Maron","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2025.102658_bib5","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0140-6736(12)60397-3","article-title":"Hypertrophic cardiomyopathy","volume":"381","author":"Maron","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2025.102658_bib6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.amjmed.2016.09.015","article-title":"Nonobstructive hypertrophic cardiomyopathy out of the shadows: known from the beginning but largely ignored \u2026 until now","volume":"130","author":"Maron","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.jchf.2025.102658_bib7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijcard.2010.08.026","article-title":"Chronotropic incompetence and its relation to exercise intolerance in hypertrophic cardiomyopathy","volume":"153","author":"Efthimiadis","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib8","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Ommen","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib9","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1253\/circj.CJ-12-1561","article-title":"Clinical characteristics and natural history of hypertrophic cardiomyopathy with midventricular obstruction","volume":"77","author":"Efthimiadis","year":"2013","journal-title":"Circ J"},{"key":"10.1016\/j.jchf.2025.102658_bib10","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015294","article-title":"Apical hypertrophic cardiomyopathy: the variant less known","volume":"9","author":"Hughes","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jchf.2025.102658_bib11","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.3390\/jcm10091954","article-title":"Hypertrophic cardiomyopathy and primary restrictive cardiomyopathy: similarities, differences and phenocopies","volume":"10","author":"Vio","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jchf.2025.102658_bib12","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.124.069378","article-title":"Long-term outcomes after septal reduction therapies in obstructive hypertrophic cardiomyopathy: insights from the SHARE registry","volume":"150","author":"Maurizi","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2025.102658_bib13","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006657","article-title":"Clinical outcomes in patients with nonobstructive, labile, and obstructive hypertrophic cardiomyopathy","volume":"7","author":"Lu","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jchf.2025.102658_bib14","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2016.01.023","article-title":"Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy","volume":"67","author":"Maron","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib15","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.amjcard.2015.06.018","article-title":"Comparison of outcomes in patients with nonobstructive, labile-obstructive, and chronically obstructive hypertrophic cardiomyopathy","volume":"116","author":"Pozios","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib16","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ijcard.2017.06.071","article-title":"Long-term outcome of nonobstructive versus obstructive hypertrophic cardiomyopathy: a systematic review and meta-analysis","volume":"243","author":"Pelliccia","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib17","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2025.102658_bib18","first-page":"754","article-title":"The diagnostic and therapeutic implications of phenocopies and mimics of hypertrophic cardiomyopathy","volume":"40","author":"Bakalakos","year":"2024","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib19","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2025.102658_bib20","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jcmg.2023.07.012","article-title":"Improved diagnostic criteria for apical hypertrophic cardiomyopathy","volume":"17","author":"Hughes","year":"2024","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jchf.2025.102658_bib21","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jacc.2024.10.082","article-title":"Demographic-based personalized left ventricular hypertrophy thresholds for hypertrophic cardiomyopathy diagnosis","volume":"85","author":"Shiwani","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib22","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ijcard.2014.09.001","article-title":"Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance","volume":"177","author":"Smid","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib23","article-title":"Diagnostic significance of paradoxical left ventricular hypertrophy in detecting cardiac amyloidosis","volume":"49","author":"Ota","year":"2023","journal-title":"Int J Cardiol Heart Vasc"},{"key":"10.1016\/j.jchf.2025.102658_bib24","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib25","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012250","article-title":"Prevalence of unexplained left ventricular hypertrophy by cardiac magnetic resonance imaging in MESA","volume":"8","author":"Massera","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jchf.2025.102658_bib26","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1001\/jamacardio.2021.0689","article-title":"Prevalence of hypertrophic cardiomyopathy in the UK Biobank population","volume":"6","author":"Lopes","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41569-020-0428-2","article-title":"Epidemiology of the inherited cardiomyopathies","volume":"18","author":"McKenna","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib28","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1136\/heartjnl-2021-320181","article-title":"Epidemiology of cardiomyopathies and incident heart failure in a population-based cohort study","volume":"108","author":"Brownrigg","year":"2022","journal-title":"Heart"},{"key":"10.1016\/j.jchf.2025.102658_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191214","article-title":"Identifying unmet clinical need in hypertrophic cardiomyopathy using national electronic health records","volume":"13","author":"Pujades-Rodriguez","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jchf.2025.102658_bib30","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s11897-021-00526-x","article-title":"Sex differences in hypertrophic cardiomyopathy: Interaction with genetics and environment","volume":"18","author":"Butters","year":"2021","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.jchf.2025.102658_bib31","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ajhg.2012.07.017","article-title":"Burden of rare sarcomere gene variants in the Framingham and Jackson Heart Study cohorts","volume":"91","author":"Bick","year":"2012","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jchf.2025.102658_bib32","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jacc.2021.07.017","article-title":"Phenotypic expression and outcomes in individuals with rare genetic variants of hypertrophic cardiomyopathy","volume":"78","author":"de Marvao","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib33","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.122.003704","article-title":"Prevalence and disease expression of pathogenic and likely pathogenic variants associated with inherited cardiomyopathies in the general population","volume":"15","author":"Bourfiss","year":"2022","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.jchf.2025.102658_bib34","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jchf.2023.07.023","article-title":"Predicted deleterious variants in cardiomyopathy genes prognosticate mortality and composite outcomes in the UK Biobank","volume":"12","author":"Asatryan","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2025.102658_bib35","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.hrthm.2019.04.040","article-title":"Risk factors for lethal arrhythmic events in children and adolescents with hypertrophic cardiomyopathy and an implantable defibrillator: an international multicenter study","volume":"16","author":"Balaji","year":"2019","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jchf.2025.102658_bib36","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jamacardio.2019.2861","article-title":"Development of a novel risk prediction model for sudden cardiac death in childhood hypertrophic cardiomyopathy (HCM Risk-Kids)","volume":"4","author":"Norrish","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib37","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/eurheartj\/eht439","article-title":"A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD)","volume":"35","author":"O'Mahony","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2025.102658_bib38","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.jacc.2005.04.062","article-title":"Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients","volume":"46","author":"Biagini","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib39","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1161\/CIRCULATIONAHA.105.583500","article-title":"Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy","volume":"114","author":"Harris","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2025.102658_bib40","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3390\/jcm10081547","article-title":"Left ventricular remodeling in hypertrophic cardiomyopathy: an overview of current knowledge","volume":"10","author":"Musumeci","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jchf.2025.102658_bib41","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jchf.2014.06.012","article-title":"Long-term outcomes after medical and invasive treatment in patients with hypertrophic cardiomyopathy","volume":"2","author":"Vriesendorp","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2025.102658_bib42","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jacc.2016.11.063","article-title":"Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and management","volume":"69","author":"Rowin","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib43","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/ehjci\/jeaa246","article-title":"Apical hypertrophic cardiomyopathy with left ventricular apical aneurysm: prevalence, cardiac magnetic resonance characteristics, and prognosis","volume":"21","author":"Yang","year":"2020","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jchf.2025.102658_bib44","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.mayocp.2016.01.002","article-title":"The natural history of nonobstructive hypertrophic cardiomyopathy","volume":"91","author":"Hebl","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jchf.2025.102658_bib45","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1016\/j.jacc.2020.05.009","article-title":"Avoiding burnout from hypertrophic cardiomyopathy","volume":"75","author":"Brinkley","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib46","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1016\/j.jacc.2020.04.045","article-title":"Outcomes in patients with hypertrophic cardiomyopathy and left ventricular systolic dysfunction","volume":"75","author":"Rowin","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.131784","article-title":"Clinical characteristics and outcome of end stage hypertrophic cardiomyopathy: role of age and heart failure phenotypes","volume":"400","author":"Musumeci","year":"2024","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib48","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1161\/CIRCHEARTFAILURE.114.001843","article-title":"Clinical spectrum, therapeutic options, and outcome of advanced heart failure in hypertrophic cardiomyopathy","volume":"8","author":"Pasqualucci","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2025.102658_bib49","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1016\/j.jacc.2007.02.061","article-title":"Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype","volume":"49","author":"Kubo","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib50","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jchf.2024.11.013","article-title":"Mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy: design, rationale, and baseline characteristics of ODYSSEY-HCM","volume":"13","author":"Desai","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2025.102658_bib51","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1161\/CIRCRESAHA.121.318346","article-title":"Molecular genetic basis of hypertrophic cardiomyopathy","volume":"128","author":"Marian","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.jchf.2025.102658_bib52","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jacc.2024.12.010","article-title":"Genes associated with hypertrophic cardiomyopathy: a reappraisal by the ClinGen Hereditary Cardiovascular Disease Gene Curation Expert Panel","volume":"85","author":"Hespe","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib53","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jacc.2020.05.029","article-title":"Clinical features and natural history of PRKAG2 variant cardiac glycogenosis","volume":"76","author":"Lopez-Sainz","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib54","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa033349","article-title":"Glycogen storage diseases presenting as hypertrophic cardiomyopathy","volume":"352","author":"Arad","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2025.102658_bib55","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jamacardio.2022.1061","article-title":"Rare and common genetic variation underlying the risk of hypertrophic cardiomyopathy in a national biobank","volume":"7","author":"Biddinger","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib56","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41588-020-00764-0","article-title":"Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity","volume":"53","author":"Harper","year":"2021","journal-title":"Nat Genet"},{"key":"10.1016\/j.jchf.2025.102658_bib57","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1161\/CIRCULATIONAHA.110.978924","article-title":"Genetics and clinical destiny: improving care in hypertrophic cardiomyopathy","volume":"122","author":"Ho","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2025.102658_bib58","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1136\/heartjnl-2014-306387","article-title":"Novel genotype-phenotype associations demonstrated by high-throughput sequencing in patients with hypertrophic cardiomyopathy","volume":"101","author":"Lopes","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.jchf.2025.102658_bib59","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s00392-017-1155-5","article-title":"Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals","volume":"107","author":"Sedaghat-Hamedani","year":"2018","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib60","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.amjcard.2016.06.038","article-title":"Value of genetic testing for the prediction of long-term outcome in patients with hypertrophic cardiomyopathy","volume":"118","author":"van Velzen","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib61","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00392-023-02310-4","article-title":"Improving sudden cardiac death risk stratification in hypertrophic cardiomyopathy using established clinical variables and genetic information","volume":"113","author":"Amr","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib62","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.jacc.2019.08.1057","article-title":"Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM Registry","volume":"74","author":"Neubauer","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib63","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41588-020-00762-2","article-title":"Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect","volume":"53","author":"Tadros","year":"2021","journal-title":"Nat Genet"},{"key":"10.1016\/j.jchf.2025.102658_bib64","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41588-025-02087-4","article-title":"Large scale genome-wide association analyses identify novel genetic loci and mechanisms in hypertrophic cardiomyopathy","volume":"57","author":"Tadros","year":"2025","journal-title":"Nat Genet"},{"key":"10.1016\/j.jchf.2025.102658_bib65","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41588-025-02094-5","article-title":"Evaluation of polygenic scores for hypertrophic cardiomyopathy in the general population and across clinical settings","volume":"57","author":"Zheng","year":"2025","journal-title":"Nat Genet"},{"key":"10.1016\/j.jchf.2025.102658_bib66","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1038\/s41467-018-06191-4","article-title":"Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibition","volume":"9","author":"Robert-Paganin","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jchf.2025.102658_bib67","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jchf.2025.102658_bib68","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib69","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1161\/CIRCULATIONAHA.122.062534","article-title":"Dose-blinded myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: outcomes through 32 weeks","volume":"147","author":"Desai","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2025.102658_bib70","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial","volume":"8","author":"Desai","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib71","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.122.014986","article-title":"Myosin inhibition and left ventricular diastolic function in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: insights from the VALOR-HCM study","volume":"15","author":"Cremer","year":"2022","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jchf.2025.102658_bib72","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2025.102658_bib73","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.jacc.2021.09.1381","article-title":"Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Hegde","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib74","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.120.052359","article-title":"Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM cardiac magnetic resonance substudy analysis","volume":"143","author":"Saberi","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2025.102658_bib75","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/ejhf.2737","article-title":"Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy","volume":"25","author":"Wheeler","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2025.102658_bib76","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1001\/jamacardio.2022.5099","article-title":"Effects of mavacamten on measures of cardiopulmonary exercise testing beyond peak oxygen consumption: a secondary analysis of the EXPLORER-HCM randomized trial","volume":"8","author":"Wheeler","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib77","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/jamacardio.2023.3030","article-title":"Effect of mavacamten on Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: the EXPLORER-CN randomized clinical trial","volume":"8","author":"Tian","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib78","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jchf.2025.102658_bib79","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jchf.2023.09.028","article-title":"Mavacamten treatment for symptomatic obstructive hypertrophic cardiomyopathy: interim results from the MAVA-LTE study, EXPLORER-LTE cohort","volume":"12","author":"Rader","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2025.102658_bib80","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1093\/eurheartj\/ehae579","article-title":"Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Garcia-Pavia","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2025.102658_bib81","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/S0140-6736(21)00763-7","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Spertus","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jchf.2025.102658_bib82","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jchf.2024.03.009","article-title":"Real-world experience and 36-week outcomes of patients with symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten","volume":"12","author":"Reza","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2025.102658_bib83","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1429230","article-title":"One-year real-world experience with mavacamten and its physiologic effects on obstructive hypertrophic cardiomyopathy","volume":"11","author":"Kim","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jchf.2025.102658_bib84","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.cell.2016.04.002","article-title":"A tension-based model distinguishes hypertrophic versus dilated cardiomyopathy","volume":"165","author":"Davis","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jchf.2025.102658_bib85","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.86898","article-title":"Molecular profiling of dilated cardiomyopathy that progresses to heart failure","volume":"1","author":"Burke","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jchf.2025.102658_bib86","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41586-022-04817-8","article-title":"Single-nucleus profiling of human dilated and hypertrophic cardiomyopathy","volume":"608","author":"Chaffin","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jchf.2025.102658_bib87","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1161\/01.CIR.97.25.2536","article-title":"31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy","volume":"97","author":"Jung","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2025.102658_bib88","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/S0735-1097(02)03009-7","article-title":"Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy","volume":"41","author":"Crilley","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib89","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1161\/CIRCULATIONAHA.109.934059","article-title":"Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy","volume":"122","author":"Abozguia","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jchf.2025.102658_bib90","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jamacardio.2018.4847","article-title":"Effect of trimetazidine dihydrochloride therapy on exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy: a randomized clinical trial","volume":"4","author":"Coats","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib91","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1253\/circj.CJ-20-0910","article-title":"JCS\/JHFS 2018 guideline on the diagnosis and treatment of cardiomyopathies","volume":"85","author":"Kitaoka","year":"2021","journal-title":"Circ J"},{"key":"10.1016\/j.jchf.2025.102658_bib92","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.3390\/jcm12103481","article-title":"Cardiac magnetic resonance in HCM phenocopies: from diagnosis to risk stratification and therapeutic management","volume":"12","author":"Licordari","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.jchf.2025.102658_bib93","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1136\/hrt.2003.014969","article-title":"Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography","volume":"90","author":"Moon","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.jchf.2025.102658_bib94","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1093\/eurheartj\/ehaf026","article-title":"Hypertrophic cardiomyopathy: prevalence of disease-specific red flags","volume":"46","author":"Maurizi","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2025.102658_bib95","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/europace\/euac030","article-title":"European Heart Rhythm Association (EHRA)\/Heart Rhythm Society (HRS)\/Asia Pacific Heart Rhythm Society (APHRS)\/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases","volume":"24","author":"Wilde","year":"2022","journal-title":"EP Europace"},{"key":"10.1016\/j.jchf.2025.102658_bib96","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s41687-020-00269-8","article-title":"Patient experiences with hypertrophic cardiomyopathy: a conceptual model of symptoms and impacts on quality of life","volume":"4","author":"Zaiser","year":"2020","journal-title":"J Patient Rep Outcomes"},{"key":"10.1016\/j.jchf.2025.102658_bib97","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jchf.2022.03.002","article-title":"Validation of the Kansas City Cardiomyopathy Questionnaire in symptomatic obstructive hypertrophic cardiomyopathy","volume":"10","author":"Nassif","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2025.102658_bib98","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/ehjqcco\/qcae092","article-title":"Loss of quality of life and increased societal costs in patients with hypertrophic cardiomyopathy: the AFFECT-HCM study","volume":"11","author":"Schoonvelde","year":"2025","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.jchf.2025.102658_bib99","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.124.011663","article-title":"Quality of life and exercise capacity in early stage and subclinical hypertrophic cardiomyopathy: a secondary analysis of the VANISH trial","volume":"17","author":"Ireland","year":"2024","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2025.102658_bib100","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s41669-022-00335-5","article-title":"Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): a new patient-reported outcome (PRO) instrument","volume":"6","author":"Reaney","year":"2022","journal-title":"Pharmacoecon Open"},{"key":"10.1016\/j.jchf.2025.102658_bib101","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.jacc.2022.08.715","article-title":"Impact of exercise on outcomes and phenotypic expression in athletes with nonobstructive hypertrophic cardiomyopathy","volume":"80","author":"Basu","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib102","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijcard.2017.07.015","article-title":"Vigorous exercise in patients with hypertrophic cardiomyopathy","volume":"250","author":"Dejgaard","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib103","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jacc.2022.07.013","article-title":"Athletic activity for patients with hypertrophic cardiomyopathy and other inherited cardiovascular diseases: JACC focus seminar 3\/4","volume":"80","author":"Semsarian","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib104","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jtcvs.2019.03.088","article-title":"Apical myectomy for patients with hypertrophic cardiomyopathy and advanced heart failure","volume":"159","author":"Nguyen","year":"2020","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jchf.2025.102658_bib105","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1161\/CIRCHEARTFAILURE.114.001435","article-title":"Advanced heart failure with preserved systolic function in nonobstructive hypertrophic cardiomyopathy: under-recognized subset of candidates for heart transplant","volume":"7","author":"Rowin","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2025.102658_bib106","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1161\/CIRCHEARTFAILURE.109.922872","article-title":"Survival after cardiac transplantation in patients with hypertrophic cardiomyopathy","volume":"3","author":"Maron","year":"2010","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2025.102658_bib107","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.hrthm.2023.05.021","article-title":"Optimizing diastolic filling by pacing in nonobstructive hypertrophic cardiomyopathy","volume":"20","author":"Subramanian","year":"2023","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jchf.2025.102658_bib108","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/ejhf.1722","article-title":"Biventricular pacemaker therapy improves exercise capacity in patients with non-obstructive hypertrophic cardiomyopathy via augmented diastolic filling on exercise","volume":"22","author":"Ahmed","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2025.102658_bib109","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacep.2018.08.018","article-title":"Benefit of cardiac resynchronization therapy in end-stage nonobstructive hypertrophic cardiomyopathy","volume":"5","author":"Rowin","year":"2019","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.jchf.2025.102658_bib110","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ejheart.2008.03.006","article-title":"Effect of biventricular pacing on symptoms and cardiac remodelling in patients with end-stage hypertrophic cardiomyopathy","volume":"10","author":"Rogers","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2025.102658_bib111","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/s41591-021-01505-4","article-title":"Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial","volume":"27","author":"Ho","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jchf.2025.102658_bib112","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/ejhf.3291","article-title":"Sacubitril\/valsartan for the treatment of non-obstructive hypertrophic cardiomyopathy: an open label randomized controlled trial (SILICOFCM)","volume":"26","author":"Velicki","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jchf.2025.102658_bib113","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004124","article-title":"Efficacy of ranolazine in patients with symptomatic hypertrophic cardiomyopathy: the RESTYLE-HCM randomized, double-blind, placebo-controlled study","volume":"11","author":"Olivotto","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2025.102658_bib114","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002764","article-title":"Novel approach targeting the complex pathophysiology of hypertrophic cardiomyopathy: the impact of late sodium current inhibition on exercise capacity in subjects with symptomatic hypertrophic cardiomyopathy (LIBERTY-HCM) trial","volume":"9","author":"Olivotto","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2025.102658_bib115","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.amjmed.2018.02.025","article-title":"Effect of spironolactone on myocardial fibrosis and other clinical variables in patients with hypertrophic cardiomyopathy","volume":"131","author":"Maron","year":"2018","journal-title":"Am J Med"},{"key":"10.1016\/j.jchf.2025.102658_bib116","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S2213-8587(14)70241-4","article-title":"Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial","volume":"3","author":"Axelsson","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jchf.2025.102658_bib117","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/heartjnl-2015-308343","article-title":"Functional effects of losartan in hypertrophic cardiomyopathy\u2014a randomised clinical trial","volume":"102","author":"Axelsson","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.jchf.2025.102658_bib118","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ahj.2021.06.010","article-title":"Randomized controlled trial of perhexiline on regression of left ventricular hypertrophy in patients with symptomatic hypertrophic cardiomyopathy (RESOLVE-HCM trial)","volume":"240","author":"Ananthakrishna","year":"2021","journal-title":"Am Heart J"},{"key":"10.1016\/j.jchf.2025.102658_bib119","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40265-022-01728-w","article-title":"Pharmacological management of hypertrophic cardiomyopathy: from bench to bedside","volume":"82","author":"Palandri","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.jchf.2025.102658_bib120","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006231","article-title":"Baseline characteristics of the VANISH cohort","volume":"12","author":"Axelsson Raja","year":"2019","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jchf.2025.102658_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2025.01.021","article-title":"The antifibrotic effects of eplerenone in hypertrophic cardiomyopathy: a randomized clinical trial","volume":"13","author":"Papapostolou","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2025.102658_bib122","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib123","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cardfail.2024.02.020","article-title":"Efficacy and safety of aficamten in symptomatic nonobstructive hypertrophic cardiomyopathy: results from the REDWOOD-HCM trial, cohort 4","volume":"30","author":"Masri","year":"2024","journal-title":"J Card Fail"},{"key":"10.1016\/j.jchf.2025.102658_bib124","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jchf.2025.102658_bib126","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0735-1097(21)01539-4","article-title":"Phase 1 safety and tolerability study of IMB-1018972, a novel oral modulator of myocardial substrate utilization designed to improve cardiac metabolic efficiency and bioenergetics","volume":"77","author":"Chamberlin","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib127","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.jacc.2024.03.387","article-title":"Safety and efficacy of metabolic modulation with ninerafaxstat in patients with nonobstructive hypertrophic cardiomyopathy","volume":"83","author":"Maron","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib129","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1002\/ehf2.13169","article-title":"Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis","volume":"7","author":"Butler","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jchf.2025.102658_bib130","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/dom.13648","article-title":"Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis","volume":"21","author":"Toyama","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jchf.2025.102658_bib131","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s10741-021-10083-z","article-title":"SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis","volume":"27","author":"Barbarawi","year":"2022","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jchf.2025.102658_bib132","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1007\/s11255-023-03586-1","article-title":"The efficacy and safety of SGLT2 inhibitors in patients with non-diabetic chronic kidney disease: a systematic review and meta-analysis","volume":"55","author":"Ma","year":"2023","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.jchf.2025.102658_bib133","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2025.102658_bib134","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.amjcard.2022.10.054","article-title":"Efficacy of SGLT2 inhibitors in patients with diabetes and nonobstructive hypertrophic cardiomyopathy","volume":"188","author":"Subramanian","year":"2023","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jchf.2025.102658_bib137","doi-asserted-by":"crossref","first-page":"36","DOI":"10.15420\/aer.2013.2.1.36","article-title":"Mimics of hypertrophic cardiomyopathy\u2014diagnostic clues to aid early identification of phenocopies","volume":"2","author":"Sankaranarayanan","year":"2013","journal-title":"Arrhythm Electrophysiol Rev"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177925005864?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177925005864?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T11:35:08Z","timestamp":1774956908000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177925005864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":133,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2213177925005864"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2025.102658","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathophysiology and Therapeutic Needs in Nonobstructive Hypertrophic Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2025.102658","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102658"}}